Connect with us

Cannabis

How Much is US Progressing in Medical Cannabis?

Published

on

progressing

When US states are legalizing cannabis for medical and recreational purposes, cannabis for long term use is progressing. Few states report having lesser patient traffic in their healthcare facilities after the accessibility of medical cannabis.

Mostly the decrease is from the customers who received their medical cards in their regions as it was the only means through which they could buy cannabis legally and discarded as the more lenient legalization was made possible.

For people relying completely on medical cannabis to treat or manage their medical conditions like chronic pain or cancer-related emesis, this legalization of cannabis for it means even lesser options and more cost.

Medical patient data in the state of Oregon

The medical plan declined after the legalization of cannabis for recreational purposes in Oregon. Consequently, two-thirds of the patients discarded the medical cards according to statistics. With the exiting of the patients, the medical stores declined drastically from 400 to only two. Moreover, many cultivators who had a contract with patients on individual levels walked away from growing specific strains.

Around 28,000 patients are in a struggle to find the right cannabis products for the cure of their progressing diseases. The state is not providing a sufficient number of options for the people to get access to medical cannabis. Even the edibles and hemp oils are getting way out of the budget.

10 states that have legalized cannabis

Out of the total, at this point, ten US states have fully legalized cannabis for all purposes. Colorado, Nevada, Oregon, and Alaska have synergistic data stored of patients and the market for recreational cannabis.

Alaska faced the second biggest decrease. 63% of medical patients having cards dropped them soon after cannabis got fully legal for recreational purposes in 2016. Nevada faced a 40% decline in 2017. Colorado, on the other end, faced a decline of 19% since legalization in 2014.

California sells the product on the largest legal scale. The state does not keep any data from its patients. With the debut of cannabis for recreational purposes since last year, the communities are under damage. It is due to the presence of unlicensed cooperatives for cannabis. Patients had been sharing their home cultivated cannabis for free.

There is a lack of enough data that supports the health claims the advocates for medical cannabis made. Additionally, the United States Government still includes cannabis under the list of controlled substances, just like some drugs.

Situation in more conservative states

However, the popularity of medical cannabis is on the rise with more states legalizing it. The total count is thirty-three, Utah, and Oklahoma is one of the recent ones. Oklahoma had recently issued a hundred thousand licenses to patients since the cannabis legalization last year.

An accurate and progressing statistical analysis of patients is not possible at the current moment as few states like California do not keep track of their patients. However, excluding these states, about 1.4 million people had been actively involved in the cannabis program last year. The probability is that on the addition of the few states that haven’t been keeping the data, the number will increase up to another million.

With more states legalizing cannabis for recreational and medical purposes, some communities that solely consume it for medical reasons are feeling left out.

The edibles potency is not coming under the spotlight since after the wide spreading legalization. It means that patients have been paying more for the same dose of cannabis as they had been paying before the full legalization.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Cannabis And The Mental Health – The Risks Involved

Published

on

The cannabis plant consists of over 500 identified chemical constituents, out of which over 100 are cannabinoids. Cannabinoids interact with the endocannabinoid system – a naturally occurring communication network that exists in our brains and bodies. Varying amounts and combinations of the dosages of cannabis, can, in turn, affect several physiological and psychological processes in different ways such as – gastrointestinal function, appetite, pain, memory, movement, immunity, inflammation, and mental health are all included.

The complexity of cannabis, however, is what makes it a potential medication for numerous illnesses. The concern is the gap that exists between the hype about cannabis, and the research with evidence supporting the hype. The concern holds a lot of relevance to mental health, where the effectiveness of cannabis as a treatment for a variety of psychiatric conditions, such as depression, anxiety, post-traumatic stress, psychosis, and addiction, is touted.

However, the reality of cannabis is that it cannot be held on the extremes of being either strictly helpful or strictly harmful. Instead, discussion regarding the potential benefits and harms of cannabis are encouraged, but with careful and nuanced consideration of science, with an addition of a humble attitude.

The science regarding the role of the endocannabinoid system in mood regulation is very clear with respect to depression. The use of cannabis or particular cannabinoids, in the treatment of depressive disorders, has had no support from any randomized controlled trials yet. On the contrary, the existing scientific data is mixed and tilts towards the idea of the worsening and development of depressive symptoms, by the ingestion of cannabis plant material. Although these findings are not satisfying, they aren’t straightforward either.

Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two best-known examples of cannabinoids found in the cannabis plant. Generally, the production of anxiety and psychotic features has been shown by THC, especially at higher doses. Meanwhile, production of anxiolytic and antipsychotic effects have been shown by CBD

However, a person’s increased or decreased anxiety or psychotic symptoms after ingesting cannabis can be affected by several other variables. This could include

  • Potency levels – Any presence of other cannabis-related chemicals
  • The amount of cannabis used
  • The frequency of use by the patient
  • Any past experience with cannabis
  • The patient’s likelihood to develop and/or experience psychiatric symptoms

There is added confusion regarding the relationship between cannabis and addiction. According to scientific literature, a substantial minority of users could hold the possibility of cannabis addiction – euphoric effects of THC are expected to be held somewhat responsible for the addictive potential. This includes the possibility of cannabis addiction in one in ten people, which still holds the representation of a large number of people.

A replacement to opioids by cannabis is encouraged if the goal of the treatment would be the reduction of harm. However, cannabis treatment for other substance addictions is not the most ideal option. Addiction involves more complications than cannabis itself. That may be the reason that cannabis-based medicines cannot be the solution to the treatment of addiction, even while it may play a helpful role in it. Solutions of addiction may continue to be multipronged as the causes of it are multifaceted.

In conclusion, the person’s motive for cannabis use matters. Temporary relief and avoidance from uncomfortable thoughts and emotions may be provided by the use of cannabis but psychiatric and psychological treatments focus on the skills and coping mechanisms to confront the difficult thoughts and emotions. Research shows, use of cannabis with this motive could ultimately lead to difficulties with mental health symptoms, and addiction. Positive and negative reinforcement could be caused by mind-altering substances such as high THC cannabis products.

 

Continue Reading

Cannabis

Glaucoma and Cannabis : What Opthalmologists Have To Say

Published

on

Myths can stay around for a long time. One of them was about Cannabis being a potential treatment for glaucoma patients. Glaucoma is a complex eye condition that involves the damage of the optic nerve over time, initially reducing peripheral vision and ultimately leading to blindness. The higher than normal eye pressure (intraocular pressure or IOP) is one of the major causes of optic nerve damage.

With the legalization of medical and recreational cannabis use in more U.S. states and Canada, researchers have been studying the use of cannabis as possible treatments for various health conditions. Although research from the 1970s and 1980s has shown a detectable drop in intraocular pressure for three to four hours, after the consumption of cannabis – by smoking, or by the ingestion of TH in the form of pills or injection, treatment for glaucoma would require control of eye pressure for a complete 24 hours.

Studies show that ingestion of about 18 to 20 mg of THC, six to eight times daily, is required for the reduction and maintenance of intraocular pressure by 3 to 5 mm Hg. This could also include significant negative effects on mood, mental clarity, and lung health (if smoked). Driving, operation of machinery, or engagement in various common activities would be prohibited. Additionally, the amount of cannabis needed to be consumed every three to four hours makes it cost-prohibitive for a significant number of patients.

Comparatively, alcohol has moderate intraocular pressure-lowering effects for an hour after consumption. However, the consumption of alcohol would never be recommended by doctors as a treatment for glaucoma.

Is THC Effective or Reliable as a Treatment for Glaucoma?

THC eye drops, pills and cigarettes have been studied, and the results aren’t positive. Burning and irritated eyes were caused by eye drops, with no decrease in eye pressure. Similarly, no decrease in eye pressure was recorded, after the use of sublingual THC compounds either. Meanwhile, use of THC-containing pills and/or cigarettes was stopped by patients after 9 months, due to the side effects.

With further research about glaucoma, scientists have concluded that the high intraocular pressure in the fluid at the front of the eye, is not the sole cause of the optic nerve damage. Further evidence shows that another cause could be the reduced blood flow in the optic nerve. While cannabis may lower eye pressure, it also lowers the patient’s blood pressure. Thus, the potential of cannabis to lower blood pressure effectively cancels out its ability to lower intraocular pressure.

What About CBD?

Currently available cannabis and cannabis-derived compounds – like CBD is not a sufficient treatment for any eye condition, including glaucoma. Cannabis is not a practical treatment to maintain lowered eye pressure for 24 hours, in order to treat glaucoma.

CBD has gained a lot of attention and scrutiny in the last few years. Although CBD is a derivative of cannabis as well, it doesn’t cause any mood-altering effects. However, current research does not support the use of CBD as an effective treatment for glaucoma. On the contrary, a recent study has shown that an increase in IOP may be caused by the CBD, making glaucoma worse.

The Future of Cannabis For Glaucoma Treatment

Currently, ophthalmologists say that the only way to control glaucoma and control vision is to lower the patient’s intraocular pressure. Depending on the type of glaucoma and severity, ophthalmologists can use medications such as prescription eye drops or surgery, as a form of treatment for glaucoma.

Furthermore, cannabis or any other cannabis products are NOT RECOMMENDED for the treatment of glaucoma, by the American Academy of Opthalmology, along with the agreement of the American Glaucoma Society and the Canadian Opthalmological Society.

Continue Reading

Cannabis

Global Pandemic Gives Rise To Huge Sales Spikes For Cannabis

Published

on

Cannabis sales increase across US and Canada as lockdown continues. The population rushes to stockpile cannabis to prepare itself for the long period of self-isolation, due to the spread of the COVID-19 pandemic.

Between the time period of March 16 and March 22, key US markets, including California, Colorado, Oregon, and Alaska, experienced a 50 percent rise in sales of recreational cannabis, and a 41 percent rise in medical cannabis sales, from the same period last year, figures attained from cannabis point of sale and info system Flowhub exhibit.

With the death toll rising to 600 in both countries, several US states and Canadian provinces are issuing stay at home orders, limiting business operations, and closing down borders, in an attempt to actively work to combat the fast-spreading coronavirus.

Although many businesses have been shut down due to the orders of a lockdown, legalized cannabis dispensaries are allowed to continue their businesses despite the current crisis, and have been listed as “essential services” alongside hospitals and other health facilities, even in jurisdictions with the tightest lockdown protocols,

During the intensifying threat of the COVID-19 and increasing sales of cannabis across North America, Bank of America analyst Chris Carey commented that investors could be provided with a defensive move in a market downturn, by the cannabis sector. Carey further talked about the acceleration of cannabis purchases in North America, regardless of region.

Carey pointed out Aphria specifically, boosting its rating to a “buy”. According to the BNN Bloomberg, Carey had reportedly explained how the Ontario-based grower could be expected to see it’s market share in Canada increase.

Aphria and Tilray stocks rose during the same time period. Last week, Aphria’s shares had been reported to move from a low of US$1.97 (C$2.88) to hit US$2.72 (C$3.89), between the time period of March 18th to March 20th. Closing at US$2.51 (C$3.58) last week, they gained slightly more yesterday at US$2.54 (C$3.72) to end the day.

Meanwhile during March 19 to March 20, Tilry shares had risen twice as much, from a low US$2.56 to a high of US$5.03. Yesterday, the stock closed at US$3.85.

According to the OCS Director of Communications Daffyd Roderick, Canada’s most populated province, Ontario, the government-run Ontario Cannabis Store’s (OCS) website experienced escalating online sales in the last two weeks. Last weekend, orders were reported to be more than twice as high compared to two weeks ago.

On Sunday, Nova Scotia was reported to be the latest province to announce a COVID-19 emergency. The province’s liquor commission, that is responsible for the control of sales of cannabis in Nova Scotia, reported a spike of 76 percent in cannabis sales last week.

Sales were also booming in cannabis related beverage companies. One such case was reported by Jamie Pearson, CEO of California-based Bhang Inc, who makes and deals with cannabis-infused beverages, chocolates, and other products. Hence, Pearson is expecting boosted revenue and profits this quarter.

Pearson further claimed the most popular products to be edibles such as gummies, brownies, and chocolates, because of easier storage and accessibility even with precautions such as having gloves on.

Stuart Titus, CEO of California-based Medical Marijuana Inc informed Reuters that the reason behind the boost of Canadian sales was the fear of months of supply disruptions. However, caution is recommended by Titus and others, as they believe that the long-awaited reversal of fortune could potentially be nothing more than a short-lived relief.

Avis Bulbulyan, CEO of cannabis consulting firm Siva Enterprises, explained that even during a global crisis like the spread of the global pandemic, the cannabis industry seems to be recession-proof. Bulbulyan further added that the rise in customer demand is not expected to last very long during a time like this.

Continue Reading

Trending